[3-Chloro-5-(2,5-dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid | 1208264-86-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3-Chloro-5-(2,5-dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid
• 英文别名: 2-[[3-Chloro-5-[(2,5-dichlorophenyl)sulfonylamino]-2-fluoro-5,6,7,8-tetrahydronaphthalen-1-yl]oxy]acetic acid
• CAS: 1208264-86-1
• 化学式: C₁₈H₁₅Cl₃FNO₅S
• 分子量: 482.744
• InChiKey: STTSDWPJEWMWTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• SUBSTITUTED AMINOTETRALINES
  申请人：Firooznia Fariborz

  公开号：US20100041713A1

  公开（公告）日：2010-02-18

  The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及式I的化合物： 及其药用可接受的盐和酯，其中R1-R4在详细说明和权利要求中有定义。此外，本发明涉及制造和使用式I的化合物的方法，以及含有这种化合物的药物组合物。式I的化合物是CRTH2受体的拮抗剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• JP2011529869A
  申请人：——

  公开号：JP2011529869A

  公开（公告）日：2011-12-15
• US8263656B2
  申请人：——

  公开号：US8263656B2

  公开（公告）日：2012-09-11
• [EN] SUBSTITUTED AMINOTETRALINES<br/>[FR] AMINOTÉTRALINES SUBSTITUÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010018109A2

  公开（公告）日：2010-02-18

  The invention is concerned with the compounds of formula (I), and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.